Themis

Binah.ai and CareOS Partner to Bring Contactless Vital Signs Monitoring to Homes via Smart Mirrors

Retrieved on: 
Tuesday, March 15, 2022
Insurance, Solution, Face, Technology, Blood pressure, Health, Partnership, Organization, PRQ, TEL, AI, Heart rate, IOT, Machine learning, Tablet, Artificial intelligence, Marketing, Privacy, Data analysis, CES, Themis, Medical device, Medical imaging, Online shopping

Binah.ai technology is currently integrated into the CareOS Artmis large size mirror; and soon Themis, the CareOS' small size accessible mirror to be launched in 2023.

Key Points: 
  • Binah.ai technology is currently integrated into the CareOS Artmis large size mirror; and soon Themis, the CareOS' small size accessible mirror to be launched in 2023.
  • There is no need to purchase or secure wearables or any other dedicated hardware for measurements as the entire process is contactless.
  • For more information on Binah.ai, please visit Binah.ai's website and for more information CareOS smart mirrors visit http://www.care-os.com .
  • Embedded in a smart mirror, CareOS organizes and enhances information from connected devices, digital services and smart sensors to create new daily routines.

Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine

Retrieved on: 
Tuesday, October 29, 2019
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Medical specialties, Infectious diseases, Medicine, Coalition for Epidemic Preparedness Innovations, Epidemics, Tropical diseases, Biological weapons, Zoonoses, RTT, Lassa fever, Lassa, Vaccine, Lassa Fever, CEPI, Themis

Themis Bioscience and CEPI the Coalition for Epidemic Preparedness Innovations announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis vaccine candidate against Lassa fever.

Key Points: 
  • Themis Bioscience and CEPI the Coalition for Epidemic Preparedness Innovations announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis vaccine candidate against Lassa fever.
  • The MV-LASV Lassa fever vaccine candidate, is based on Themis proprietary measles vector platform and exclusively-licensed discoveries made at Institut Pasteur.
  • Our partnership with CEPI for Lassa fever further validates our capabilities and represents our combined commitment to tackle diseases that remain a public health threat globally.
  • Dr. Melanie Saville, Director of Vaccine Development at CEPI added: Themis was the first company CEPI partnered with to develop a vaccine against Lassa fever and MERS, two of our priority pathogens.

Themis Bioscience and ZIKAVAX Consortium Announce Initiation of Phase 1 Zika Vaccine Trial

Retrieved on: 
Tuesday, October 1, 2019
Science, Biotechnology, Pharmaceutical, Research, Health, Infectious diseases, Health, Vaccines, Medicine, Zika virus, Virology, Clinical research, Design of experiments, Zika virus vaccine, Vaccine, Clinical trial, H5N1 clinical trials, 2015–16 Zika virus epidemic, Zika, Themis

Themis Bioscience announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine.

Key Points: 
  • Themis Bioscience announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine.
  • The vaccine candidate is based on Themis proprietary measles vector platform, which includes exclusively licensed technology from Institut Pasteur.
  • The Phase 1 program and further development will be run by Themis and this first trial will evaluate the safety and immunogenicity of the candidate in healthy volunteers.
  • The observer-blinded, randomized trial will investigate the safety and tolerability of the novel Zika vaccine formulation in 48 healthy volunteers.

Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline

Retrieved on: 
Wednesday, September 18, 2019
Science, Biotechnology, Pharmaceutical, Research, Health, Clinical trials, Spacecraft, Space weather, THEMIS, THEMIS, the New Investors, Themis

Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million).

Key Points: 
  • Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million).
  • Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis Supervisory Board.
  • I would like to thank our current investors for their continued support and also welcome Walter to our Board.
  • The vaccine candidate, MV-CHIK, is Phase 3-ready with the pivotal global Phase 3 trial initiation expected in the next few months.